title: Choice of first-line treatment for metastatic prostate cancer.
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000378:metabolism / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D004967:Estrogens / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use; D017273:Goserelin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009919:Orchiectomy / Q000009:adverse effects / Q000401:mortality; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D004967:Estrogens; D017273:Goserelin; D005485:Flutamide